论文部分内容阅读
目的探讨急诊治疗重症心力衰竭的方法及临床疗效。方法 102例心力衰竭患者,随机分为对照组和观察组,各51例。对照组给予监测血压、心率等常规治疗,观察组在常规治疗的基础上给予厄贝沙坦氢氯噻嗪+美托洛尔。观察两组患者治疗前后心率、左室射血分数和治疗效果。结果治疗前两组患者心率比较差异无统计学意义(P>0.05);治疗后两组患者心率均比治疗前少,且观察组少于对照组,差异有统计学意义(P<0.05)。治疗前两组左室射血分数比较差异无统计学意义(P>0.05);治疗后两组患者左室射血分数均比治疗前高,且观察组高于对照组,差异有统计学意义(P<0.05)。对照组患者11例显效,17例有效,23例无效,总有效率为54.90%;观察组患者显效19例,有效24例,无效8例,总有效率为84.31%。观察组患者治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论急诊使用厄贝沙坦氢氯噻嗪+美托洛尔能够有效改善重症心力衰竭患者的心率、左室射血分数及心功能情况,临床效果较好,值得临床推广。
Objective To explore the method and clinical efficacy of emergency treatment of severe heart failure. Methods 102 cases of heart failure patients were randomly divided into control group and observation group, each of 51 cases. The control group was given conventional therapy such as monitoring blood pressure and heart rate. The observation group was given irbesartan hydrochlorothiazide + metoprolol on the basis of routine treatment. The heart rate, left ventricular ejection fraction and therapeutic effect of two groups before and after treatment were observed. Results There was no significant difference in heart rate between the two groups before treatment (P> 0.05). After treatment, the heart rate of the two groups was less than that before treatment, and the observation group was less than the control group. The difference was statistically significant (P <0.05). The left ventricular ejection fraction of the two groups before treatment was no significant difference (P> 0.05); after treatment, left ventricular ejection fraction in both groups were higher than before treatment, and the observation group was higher than the control group, the difference was statistically significant (P <0.05). In the control group, 11 cases were markedly effective, 17 cases were effective, 23 cases were ineffective and the total effective rate was 54.90%. In the observation group, 19 cases were markedly effective, 24 cases were effective and 8 cases were ineffective. The total effective rate was 84.31%. The total effective rate of observation group was higher than that of control group, the difference was statistically significant (P <0.05). Conclusion The use of irbesartan hydrochlorothiazide + metoprolol can effectively improve the heart rate, left ventricular ejection fraction and cardiac function in patients with severe heart failure. The clinical effect is better and is worthy of clinical promotion.